Sarraf Pasha 4

What Happened

• Sarraf Pasha, a director of Cue Biopharma, was granted 21,800 restricted stock units (RSUs) on July 9, 2026. The grant was recorded at $0.00 per share (award), so no cash transaction occurred. This is a compensation award rather than an open-market purchase or sale.

Key Details

• Transaction date: 2026-07-09; Filing date: 2026-07-10 (timely filing).
• Transaction type/code: Award/Grant (A); price reported $0.00; total shares granted: 21,800 RSUs.
• Vesting: One-third of the RSUs vest on each of July 9, 2027, July 9, 2028, and July 9, 2029, subject to continued service (footnote F1).
• Post-transaction holdings: The filing notes total holdings reflect a 1-for-30 reverse stock split effected April 22, 2026 (footnote F2). See the Form 4 for the exact post-transaction holding total.
• No sale or cash exercise occurred; grant represents equity compensation, not a directional buy/sell by the insider.

Context

• RSUs are typically compensation that convert to actual shares as they vest and generally are taxed as ordinary income at vesting; they are not an immediate cash investment by the insider. Because this is an award, it should be viewed primarily as company compensation rather than a direct signal of the insider buying or selling shares.